FORMULATION AND DEVELOPMENT OF STABLE METAXALONE NANOSUSPENSION USING 32 FACTORIAL DESIGN

Abstract

Nanosuspensions are the dispersions of nanosized particles in a suitable vehicle prepared using surfactants or solubilizers to aid in nanosize distribution. Nanosuspension is best suited for dosage form development of poorly soluble drugs. According to the biopharmaceutical classification system, drugs with poor solubility fall either in BCS class II or BCS class IV. BCS class II drugs show poor solubility and good permeability; hence their bioavailability problems can be overcome by improving their solubility. Metaxalone is one such BCS class II drug from an oxazolidin-2-one class of centrally acting muscle relaxant drugs, indicated for relief of discomforts associated with acute, painful musculoskeletal conditions. Therefore, in present investigation, nanosuspension of Metaxalone has been formulated as an attempt to improve solubility and hence the overall bioavailability of Metaxalone. Media milling technique has been employed for nanosuspension preparation. Surfactant concentration (Poloxamer 407) and stirring time has been optimized using 32 factorial design to achieve desired particle size and saturation solubility responses as dependent variables. The particle size (PS) of 215.3 nm and maximum saturation solubility (SS) of 2805μg/ml was obtained as suggested solutions from factorial design which was further confirmed using check point analysis. Interaction of surfactant concentration and stirring time and their effect on particle size and saturation solubility was predicted using the contour plots and response surface plots. The optimized formulation showed around 99% metaxalone in vitro dissolution in comparison to around 46% dissolution from SKELAXIN® tablet at 30 minutes. These methodologies could therefore be employed successfully to improve solubility of any BCS class II drug and to predict effects and interactions of many experimental variables at the same time.

Authors and Affiliations

Paras R. Vasanani, L. D. Patel, Chetan M. Detroja

Keywords

Related Articles

ANTI HYPERLIPIDEMIC POTENTIAL OF POLYHERBAL FORMULATION IN WISTAR ALBINO RATS

The present study aimed that evaluation of anti hyperlipidemic activity of Momordica charantia, stem and root of Tinospora cordifolia, whole plant of Andrographis paniculata and wood of Pterocarpus marsupium and leaves o...

ESSENTIAL OIL EXTRACTED FROM PLECTRANTHUS AMBOINICUS INDUCES APOPTOSIS IN THE LUNG CANCER CELLS VIA MITOCHONDRIAL PATHWAY

The use of medicinal plants in the form of extracts and oils dates back to pre-historic times. The aim of the study was to determine the effect of Essential oil (EO) extracted from leaves of Plectranthus amboinicus on lu...

PREPARATION AND EVALUATION OF SOLID DISPERSION OF NEBIVOLOL USING SOLVENT EVAPORATION METHOD

Nebivolol is a pharmaceutical drug used for the treatment of Hypertension. It is characterized with poor solubility which limits its absorption and dissolution rate which delays onset of action. In the present study, fif...

MEDICATION KNOWLEDGE LEVEL OF HYPERTENSIVE PATIENTS FROM SOUTH INDIAN HOSPITALS

To estimate the patient’s antihypertensive medication knowledge from south Indian population. Five hundred (500) patients were participated in this study. Out of 500, 46 patients were pre hypertensive so 456 patients wer...

3D QSAR ANALYSIS ON OXADIAZOLE DERIVATIVES AS ANTICANCER AGENTS

Three dimensional quantitative structure activity relationship (3D QSAR) study by means of partial least square regression (PLSR) method was performed on a series of 3-(Aryl)-N-(Aryl)-1, 2, 4-Oxadiazol-5-amines as antipr...

Download PDF file
  • EP ID EP625232
  • DOI 10.25004/IJPSDR.2016.080406
  • Views 92
  • Downloads 0

How To Cite

Paras R. Vasanani, L. D. Patel, Chetan M. Detroja (2016). FORMULATION AND DEVELOPMENT OF STABLE METAXALONE NANOSUSPENSION USING 32 FACTORIAL DESIGN. International Journal of Pharmaceutical Sciences and Drug Research, 8(4), 223-228. https://europub.co.uk./articles/-A-625232